Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
June-2015 Volume 11 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2015 Volume 11 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells

  • Authors:
    • Yunpeng Cheng
    • Xiaoyun Liu
    • Lijiao Zhang
    • Ying Zhang
    • Ying Liu
    • Yan Lu
    • Yinong Jiang
  • View Affiliations / Copyright

    Affiliations: Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
  • Pages: 4341-4344
    |
    Published online on: January 26, 2015
       https://doi.org/10.3892/mmr.2015.3254
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The activation of the (pro)renin receptor (PRR) may be potentially active in the development of atherosclerotic plaques independent of angiotensin II. Our previous studies demonstrated that high glucose was able to induce the activation of PRR. The present study was designed to determine the function of oxidized low‑density lipoprotein (ox‑LDL) on the expression of PRR in human aortic smooth muscle cells (HASMCs). Immunofluorescence revealed that PRR was expressed in HASMCs. HASMCs were cultured with 100 µg/ml ox‑LDL for 1, 2, 4, 6, 12 and 24 h, respectively. Subsequently, HASMCs were cultured with 25, 50, 100, 150, 200 and 300 µg/ml ox‑LDL for 6 h, respectively. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis revealed that the expression of PRR was markedly upregulated in a time‑ and concentration‑dependent manner, which peaked at 6 h and 50 µg/ml, then slowly decreased. Therefore, PRR may contribute to the atherogenesis effect induced by ox‑LDL.

Introduction

Atherosclerosis and cardiovascular disease remain one of the major causes of mortality worldwide. Ox-LDL has a central proatherogenic role in the arterial wall (1–3). It has a multitude of actions on vascular smooth muscle cells, including inducing their migration and proliferation as well as altering their phenotype to foam cells (4–6). Ox-LDL also results in the generation of reactive oxygen species (ROS) from vascular smooth muscle cells (7). Ox-LDL, through increasing ROS production, leads to an increase in the generation of a variety of growth factors, including fibroblast growth factor (8,9), insulin-like growth factor-1 (10) and epidermal growth factor (11) as well as expression of their receptors, therefore inducing vascular smooth muscle cell proliferation and hypertrophy. Ox-LDL is also able to induce apoptosis in smooth muscle cells (12).

The (pro)renin receptor (PRR) constitutes a novel component of the renin-angiotensin system (RAS) and has attracted significant attention in previous years due to its versatile functions (13). Numerous studies have verified that when the renin precursor binds to its receptor, it directly triggers angiotensin II independent reactions, which may be potentially active in the development of atherosclerotic plaques (14,15). The binding to PRR and the ability to induce a signal transduction cascade independent of the generation of angiotensin II (13,16), including the activation of mitogen-activated protein kinase (MAPK) (17) and enhancement of the phosphorylation of extracellular signal-regulated kinase (ERK1/2) (18), promotes fibrosis gene expression, including transforming growth factor-β, plasminogen activator inhibitor-1, fibronectin and collagen proteins (19,20). However, to the best of our knowledge, there is little data demonstrating the direct effect of the atherogenic condition on the PRR.

A previous study by our group demonstrated that the conditions of atherogenesis, including high glucose and high blood lipids were able to upregulate the expression of PRR in cultured human umbilical vein endothelial cells (21). Therefore, cultured human aortic smooth muscle cells (HASMCs) were utilized to investigate the effect of ox-LDL on the expression of PRR.

Materials and methods

Cell culture

HASMCs were obtained from Lifeline Cell Technology (Beijing, China) and cultured according to the manufacturer’s instructions. The cells were cultured in Vasculife SMC cell culture medium, containing VascuLife basal medium and LifeFactors SMC (cat no. LS-1040; Lifeline Cell Technology) at 37°C in an atmosphere of 95% air and 5% CO2 according to the manufacturer’s instructions. Cells were seeded in six-well plates and the culture medium was changed daily. Prior to each experimental treatment, cells were serum starved for 24 h under serum-free conditions. The concentration of human ox-LDL (24.5 nmoles of MDA/mg protein; Qingdao Haicon Biotechnology Co., Ltd., Qingdao, China) was primarily based on a previously published study demonstrating their effectiveness in vascular smooth muscle cells (21). According to these results, 100 μg/ml ox-LDL was used to stimulate HASMCs for different time periods, which were divided into 1, 2, 4, 6, 12 and 24 h subgroups. Subsequently, the strongest expression time point of PRR was selected and cells were treated with different concentrations of ox-LDL, which were divided into 25, 50, 100, 150, 200 and 300 μg/ml subgroups. At the end of each experiment, cells were harvested for the preparation of whole-cell lysates and total RNA extraction.

Immunofluorescence

The expression of PRR in HASMCs was detected using immunofluorescence staining. HASMCs were seeded at a density of 5×104 cells/ml into 24-well plates, cultivated and divided into groups. At the end of culture, the HASMCs were fixed with paraformaldehyde for 30 min. Cells were incubated with the primary antibody (polyclonal rabbit anti-human ATP6IP2 antibody; 1:700 dilution; ab64975; Abcam, Cambridge, MA, USA) at 4°C overnight. Following incubation with the fluorescein-labeled secondary antibody (fluorescein isothiocyanate-conjugated goat anti-rabbit immunoglobulin G; 1:200; sc-2012, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 37°C for 40 min, HASMCs were observed using fluorescence microscopy (DM4000 B LED; Leica, Mannheim, Germany) and images were immediately captured. The same process without the primary antibody and secondary antibody was used as a negative control. Green fluorescence of the cell membrane indicated positive expression of PRR.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted immediately from cultured cells using TRIzol reagent (Gibco-BRL, Dalian, China) according to the manufacturer’s instructions. Total RNA was reverse transcribed using the Prime Script RT reagent kit with gDNA Eraser (Perfect Real Time; Takara Bio Inc., Dalian, China). RT-qPCR was performed using SYBR Premix Ex Taq™ II (Takara Bio Inc.) with the Roche LightCycler® 480 Sequence Detection System (Roche Diagnostics GmbH, Mannheim, Germany). Samples were run in triplicate in separate tubes to permit quantification of the target gene normalized to GAPDH, which was used for equal loading. Primer sequences are shown in Table I. The PCR amplification program was as follows: 95°C for 30 sec, 95°C for 5 sec and 60°C for 20 sec for 40 cycles.

Table I

Primers used for reverse transcription-quantitative polymerase chain reaction.

Table I

Primers used for reverse transcription-quantitative polymerase chain reaction.

GeneSequence (5′–3′)
ATP6AP2
(NM_005765)
 Forward TGGAAATTGGCCTATACCAGGAG
 Reverse GTAGCCCGAGGACGATGAAAC
GAPDH
(NM_002046)
 Forward GCACCGTCAAGGCTGAGAAC
 Reverse TGGTGAAGACGCCAGTGGA
Western blot analysis

Cells were lysed in 100 μl of lysis buffer (Nanjing KeyGen Biotech. Co., Ltd., Nanjing, China). Protein concentrations were measured using a protein assay kit (Nanjing KeyGen Biotech. Co., Ltd.). The protein (25 μg) obtained from each lysate was electrophoresed on a 15% SDS-polyacrylamide gel (90 mV, 30 min; 130 mV, 90 min) and transferred onto a nitrocellulose membrane (Merck Millipore, Darmstadt, Germany) using a Mini-PROTEAN 3 system (120 mV, 1.5 h; Bio-Rad, Hercules, CA, USA). The membrane was incubated overnight with polyclonal rabbit anti-human ATP6AP2 antibody (1:700 dilution; Abcam) and polyclonal rabbit anti-human β-actin (1:500 dilution; bs-0061R; Bioss, Beijing, China). The specific binding was detected using horseradish peroxidase-labeled goat anti-rabbit IgG (1:7,500; ZSGB-BIO, Beijing, China) and an enhanced chemiluminescence detection kit (Perkin-Elmer, Waltham, MA, USA). The bands were quantified using Image Pro-Plus 5.0 software (Media Cybernetics, Rockville, MD, USA).

Statistical analysis

Standard statistical methods from the SPSS statistical analysis system 16.0 (SPSS, Inc., Chicago, IL, USA) were used. Statistical comparisons were made using a two-way analysis of variance. Data are presented as the mean ± standard error of the mean. P<0.05 was considered to indicate a statistically significant difference. Duplicate wells were analyzed for each experiment and each experiment was performed independently at least three times.

Results

PRR expression in HASMCs

Immunofluorescence techniques verified that PRR was expressed in HASMCs (Fig. 1), indicating that PRR was abundant in HASMCs and mainly present in the cell membrane and cytoplasm.

Figure 1

Expression of the (pro)renin receptor in human aortic smooth muscle cells. Nuclear staining with Hoechst. (A) Staining for (pro)renin receptor (green fluorescence). (B) Negative control (magnification, ×200).

Effect of ox-LDL on the expression of PRR at different time periods

HASMCs were incubated with a final concentration of 100 μg/ml ox-LDL for 0, 1, 2, 4, 6, 12 and 24 h. It was found that the expression of PRR was significantly upregulated by ox-LDL in a time-dependent manner (Fig. 2). The mRNA and protein expression of PRR began to increase 2 h following incubation and reached a peak level at 6 h and then decreased moderately, however, maintaining a higher level of expression than the control group at 24 h.

Figure 2

(A) Expression of the PRR in human aortic smooth muscle cells stimulated by 100 μg/ml ox-LDL for different time periods detected by reverse transcription-quantitative polymerase chain reaction and (B) western blot analysis.*P<0.05 vs. the control group. PRR, (pro)renin receptor.

Effect of ox-LDL on the expression of PRR at different concentrations

Based on the above results, HASMCs were incubated with 0, 25, 50, 100, 150, 200 and 300 μg/ml ox-LDL for 6 h, respectively. Compared with the control group, the expression of PRR mRNA increased in the group treated with 25 μg/ml, reached a peak in the 50 μg/ml group, then decreased moderately in the remaining groups (Fig. 3A), revealing a concentration-dependent effect. The expression of PRR protein was similar to that of the mRNA, however, maintained significantly higher levels than the control group following decrease (Fig. 3B).

Figure 3

(A) Expression of the PRR in human aortic smooth muscle cells stimulated by different concentrations of ox-LDL for 6 h detected by reverse transcription-quantitative polymerase chain reaction and (B) western blot analysis. *P<0.05 vs. the control group. PRR, (pro)renin receptor.

Discussion

In the present study, immunofluorescence demonstrated that PRR was expressed on the cell membrane and cytoplasm in HASMCs (Fig. 1A), which is consistent with a previous study (22) and the PRR was abundant in HASMCs.

Binding of (pro)renin to the PRR increases the catalytic activity of prorenin and renin, resulting in increased RAS activation (13). Additionally, intracellular signaling cascades, including the MAPK and ERK1/2 pathways as well as the phosphorylation of heat shock protein 27 (HSP 27) (18,23,24) are triggered, resulting in the expression of profibrotic and inflammatory molecules. These effects promote the occurrence and development of atherosclerosis.

The present study demonstrated that the expression of PRR was upregulated in a time- and concentration-dependent manner stimulated by ox-LDL, indicating that PRR is involved in ox-LDL-induced atherosclerosis. This demonstrated the effect of ox-LDL on the expression of PRR for the first time, to the best of our knowledge.

However, the mechanisms underlying atherosclerosis formation induced by ox-LDL are varied, including via its own LOX-1 receptor, promoting the generation of ROS, promoting the formation of foam cells and promoting the phenotypic transformation of SMC.

Therefore, whether the upregulation of PRR expression was induced by ox-LDL directly remains to be elucidated. Further studies are required to determine the association between PRR and LOX-1, the receptor of ox-LDL.

References

1 

Ananyeva NM, Tjurmin AV, Berliner JA, et al: Oxidized LDL mediates the release of fibroblast growth factor-1. Arterioscler Thromb Vasc Biol. 17:445–453. 1997. View Article : Google Scholar : PubMed/NCBI

2 

Li D, Liu L, Chen H, Sawamura T, Ranganathan S and Mehta JL: LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation. 107:612–617. 2003. View Article : Google Scholar : PubMed/NCBI

3 

Cai H and Harrison DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res. 87:840–844. 2000. View Article : Google Scholar : PubMed/NCBI

4 

Chisolm GM 3rd and Chai Y: Regulation of cell growth by oxidized LDL. Free Radic Biol Med. 28:1697–1707. 2000. View Article : Google Scholar : PubMed/NCBI

5 

Chai YC, Binion DG, Macklis R and Chisolm GM 3rd: Smooth muscle cell proliferation induced by oxidized LDL-borne lysophosphatidylcholine. Evidence for FGF-2 release from cells not extracellular matrix. Vascul Pharmacol. 38:229–237. 2002. View Article : Google Scholar : PubMed/NCBI

6 

Shen CM, Mao SJ, Huang GS, Yang PC and Chu RM: Stimulation of smooth muscle cell proliferation by ox-LDL- and acetyl LDL-induced macrophage-derived foam cells. Life Sci. 70:443–452. 2001. View Article : Google Scholar

7 

Hsieh CC, Yen MH, Yen CH and Lau YT: Oxidized low density lipoprotein induces apoptosis via generation of reactive oxygen species in vascular smooth muscle cells. Cardiovasc Res. 49:135–145. 2001. View Article : Google Scholar

8 

Chang PY, Luo S, Jiang T, et al: Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: Mediator role of platelet-activating factor-like phospholipids. Circulation. 104:588–593. 2001. View Article : Google Scholar : PubMed/NCBI

9 

Chen CH, Jiang W, Via DP, et al: Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation. 101:171–177. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Higashi Y, Peng T, Du J, et al: A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor. J Lipid Res. 46:1266–1277. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Gao P, Wang XM, Qian DH, et al: Induction of oxidative stress by oxidized LDL via meprinα-activated epidermal growth factor receptor in macrophages. Cardiovasc Res. 97:533–543. 2013. View Article : Google Scholar

12 

Nishio E, Arimura S and Watanabe Y: Oxidized LDL induces apoptosis in cultured smooth muscle cells: a possible role for 7-ketocholesterol. Biochem Biophys Res Commun. 223:413–418. 1996. View Article : Google Scholar : PubMed/NCBI

13 

Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T and Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 109:1417–1427. 2002. View Article : Google Scholar : PubMed/NCBI

14 

Nguyen G: Renin/prorenin receptors. Kidney Int. 69:1503–1506. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Oliver JA: Receptor-mediated actions of renin and prorenin. Kidney Int. 69:13–15. 2006. View Article : Google Scholar

16 

Funke-Kaiser H, Zollmann FS, Schefe JH and Unger T: Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res. 33:98–104. 2010. View Article : Google Scholar

17 

Sakoda M, Ichihara A, Kaneshiro Y, et al: (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res. 30:1139–1146. 2007. View Article : Google Scholar

18 

Feldt S, Batenburg WW, Mazak I, et al: Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension. 51:682–688. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Huang Y, Wongamorntham S, Kasting J, et al: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 69:105–113. 2006. View Article : Google Scholar

20 

Huang Y, Noble NA, Zhang J, Xu C and Border WA: Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 72:45–52. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Hu X: Oxidized low density lipoprotein activates ERK 1/2 pathway via (pro)renin receptor in human umbilical vein endothelial cells. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease. 10:1235–1237. 2013.In Chinese.

22 

Greco CM, Camera M, Facchinetti L, et al: Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. Cardiovasc Res. 95:366–374. 2012. View Article : Google Scholar : PubMed/NCBI

23 

Kaneshiro Y, Ichihara A, Sakoda M, et al: Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol. 18:1789–1795. 2007. View Article : Google Scholar : PubMed/NCBI

24 

Abassi Z, Winaver J and Feuerstein GZ: The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Pharmacol. 78:933–940. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Cheng Y, Liu X, Zhang L, Zhang Y, Liu Y, Lu Y and Jiang Y: Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells. Mol Med Rep 11: 4341-4344, 2015.
APA
Cheng, Y., Liu, X., Zhang, L., Zhang, Y., Liu, Y., Lu, Y., & Jiang, Y. (2015). Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells. Molecular Medicine Reports, 11, 4341-4344. https://doi.org/10.3892/mmr.2015.3254
MLA
Cheng, Y., Liu, X., Zhang, L., Zhang, Y., Liu, Y., Lu, Y., Jiang, Y."Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells". Molecular Medicine Reports 11.6 (2015): 4341-4344.
Chicago
Cheng, Y., Liu, X., Zhang, L., Zhang, Y., Liu, Y., Lu, Y., Jiang, Y."Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells". Molecular Medicine Reports 11, no. 6 (2015): 4341-4344. https://doi.org/10.3892/mmr.2015.3254
Copy and paste a formatted citation
x
Spandidos Publications style
Cheng Y, Liu X, Zhang L, Zhang Y, Liu Y, Lu Y and Jiang Y: Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells. Mol Med Rep 11: 4341-4344, 2015.
APA
Cheng, Y., Liu, X., Zhang, L., Zhang, Y., Liu, Y., Lu, Y., & Jiang, Y. (2015). Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells. Molecular Medicine Reports, 11, 4341-4344. https://doi.org/10.3892/mmr.2015.3254
MLA
Cheng, Y., Liu, X., Zhang, L., Zhang, Y., Liu, Y., Lu, Y., Jiang, Y."Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells". Molecular Medicine Reports 11.6 (2015): 4341-4344.
Chicago
Cheng, Y., Liu, X., Zhang, L., Zhang, Y., Liu, Y., Lu, Y., Jiang, Y."Effect of oxidized low-density lipoprotein on the expression of the prorenin receptor in human aortic smooth muscle cells". Molecular Medicine Reports 11, no. 6 (2015): 4341-4344. https://doi.org/10.3892/mmr.2015.3254
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team